Internal Med Medical News

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease

5. Rapid correction of low vitamin D status in nursing home residents

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

DNase1 activity in systemic lupus erythematosus patients with and without nephropathy
Rheumatology International, 10/26/09

Martinez-Valle F et al. – The objective of the study is to determine whether the activity of DNase1 is associated to the presence of nephropathy in patients with SLE. We conclude that low DNase1 activity is associated to the active phase of type III or IV nephropathy. Therefore, it is possible that this enzyme plays an important role in the development of SLE nephropathy.

Methods

45 rty-five patients affected with SLE and renal involvement analyzed
Type of renal involvement was type III or IV glomerulonephritis
At least 2 serum samples withdrawn from each patient, 1 obtained in renal flare and other obtained in period of clinical stability
C3 and C4 complement levels and anti-DNA antibodies determined
DNase1 activity measured using a radial enzyme-diffusion method

Results

Results suggest that when comparison of DNase1 activity was established between samples obtained during a phase of active renal involvement and those obtained in the clinically stable phase, no statistically significant differences found
When comparison was performed with matched samples of same patient, DNase1 activity lower when patients had active renal involvement than when samples taken in clinically stable phase
No difference in DNase1 activity observed between samples positive or negative for anti-DNA antibodies
No difference in DNase1 activity found in patients with normal or decreased levels of C3 or C4